Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: A randomized pilot study

Interactive Cardiovascular and Thoracic Surgery

Volumn 23, Issue 5, 2016, Pages 740-747

  Anastasiadis, Kyriakos ^a   Antonitsis, Polychronis ^a   Vranis, Konstantinos ^a   Kleontas, Athanassios ^a   Asteriou, Christos ^a   Grosomanidis, Vassilios ^a   Tossios, Paschalis ^a   Argiriadou, Helena ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Cardiac surgery; Coronary artery bypass grafting; Left ventricular ejection fraction; Levosimendan

Indexed keywords

LEVOSIMENDAN; PLACEBO; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FORWARD HEART FAILURE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; LUNG EXTRAVASCULAR FLUID; LUNG WEDGE PRESSURE; MALE; OXYGEN SATURATION; PILOT STUDY; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRANSTHORACIC ECHOCARDIOGRAPHY; ADVERSE EFFECTS; CARDIAC OUTPUT, LOW; COMPLICATION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; FINLAND; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATIONS; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SURVIVAL RATE; TRENDS;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; HYDRAZONES; INCIDENCE; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; PYRIDAZINES; STROKE VOLUME; SURVIVAL RATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84994592283     PISSN: 15699293     EISSN: 15699285     Source Type: Journal    
DOI: 10.1093/icvts/ivw213     Document Type: Article

References (30)

1. Mebazaa A, Pitsis AA, Rudiger A, Toller W, Longrois D, Ricksten SE et al. Clinical review: practical recommendations on the management of perioperative heart failure in cardiac surgery. Crit Care 2010;14:201
2. Rudiger A, Businger F, Streit M, Schmid ER, Maggiorini M, Follath F. Presentation and outcome of critically ill medical and cardiac-surgery patients with acute heart failure. Swiss Med Wkly 2009;139:110-6
3. Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christiakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg 1996;112:38-51
4. Shahian DM, O'Brien SM, Filardo G, Ferraris VA, Haan CK, Rich JB et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: Part1-coronary artery bypass grafting surgery. Ann Thorac Surg 2009;88:S2-22
5. Nielsen DV, Hansen MK, Johnsen SR. Health outcomes with and without use of inotropic therapy in cardiac surgery: results of a propensity score matched analysis. Anesthesiology 2014;120:1098-108
6. Landoni G, Mizzi A, Biondi-Zoccai G, Bruno G, Bignami E, Corno L et al. Reducing mortality in cardiac surgery with levosimendan: a meta-analysis of randomized controlled trials. J Cardiothorac Vasc Anesth 2010;24:51-7
7. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012; 40:634-46
8. Harrison RW, Hasselblad V, Mehta RH, Levin R, Harrington RA, Alexander JH. Effect of levosimendan on survival and adverse events after cardiac surgery: a meta-analysis. J Cardiothorac Vasc Anesth 2013;27:1224-32
9. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikäinen PJ. Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002;40:465-71
10. Moher D, Jones A, Lepage L; CONSORT Group (Consolidated Standards for Reporting of Trials). Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA 2001;285:1992-5
11. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014;46:517-92
12. Asteriou C, Antonitsis P, Argiriadou H, Deliopoulos A, Konstantinou D, Foroulis C et al. Minimal extracorporeal circulation reduces the incidence of postoperative major adverse events after elective coronary artery bypass grafting in high-risk patients. A single-institutional prospective randomized study. Perfusion 2013;28:350-6
13. Kowalewski M, Pawliszak W, Raffa GM, Malvindi PG, Kowalkowska ME, Zaborowska K et al. Safety and efficacy of miniaturized extracorporeal circulation when compared with off-pump and conventional coronary artery bypass grafting: evidence synthesis from a comprehensive Bayesian-framework network meta-analysis of 134 randomized controlled trials involving 22 778 patients. Eur J Cardiothorac Surg 2016;49:1428-40
14. Leppikangas H, Järvelä K, Sisto T, Maaranen P, Virtanen M, Lehto P et al. Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery. Br J Anaesth 2011;106:298-304
15. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007;104:766-73
16. Al-Shawaf E, Ayed A, Vislocky I, Radomir B, Dehrab N, Tarazi R. Levosimendan or milrinone in the type 2 diabetic patient with low ejection fraction undergoing elective coronary artery surgery. J Cardiothorac Vasc Anesth 2006;20:353-7
17. Toller W, Heringlake M, Guarracino F, Algotsson L, Alvarez J, Argyriadou H et al. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. Int J Cardiol 2015;184:323-36
18. Zingman LV, Alekseev AE, Hodgson-Zingman DM, Terzic A. ATP-sensitive potassium channels: metabolic sensing and cardioprotection. J Appl Physiol 2007;103:1888-93
19. Grossini E, Molinari C, Caimmi PP, Uberti F, Vacca G. Levosimendan induces NO production through p38 MAPK. ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K (ATP) channel. Br J Pharmacol 2009;156:250-61
20. De Her SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007;104:766-73
21. Kolseth SM, Nordhaug DO, Stenseth R, Sellevold O, Kirkeby-Garstad I, Wahba A. Prophylactic treatment with levosimendan: a retrospective matched-control study of patients with reduced left ventricular function. Eur J Cardiothorac Surg 2009;36:1024-30
22. Levin R, Degrange M, Del Mazo C, Tanus E, Porcile R. Preoperative levosimendan decreases mortality and the development of low cardiac output in high-risk patients with severe left ventricular dysfunction undergoing coronary artery bypass grafting with cardiopulmonary bypass. Exp Clin Cardiol 2012;17:125-30
23. Lim JY, Deo SV, Rababa'h A, Altarabsheh SE, Cho YH, Hang D et al. Levosimendan reduces mortality in adults with left ventricular dysfunction undergoing cardiac surgery: a systematic review and meta-analysis. J Card Surg 2015;30:547-54
24. Algarni KD, Maganti M, Yau TM. Predictors of low cardiac output syndrome after isolated coronary artery bypass surgery: trends over 20 years. Ann Thorac Surg 2011;92:1678-84
25. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi O, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007;9:75-82
26. Tritapepe L, De Santis V, Vitale D, Santulli M, Morelli A, Nofroni I et al. Preconditioning effects of levosimendan in coronary artery bypass grafting-A pilot study. Br J Anaesth 2006;96:694-700
27. Kowalewski M, Pawliszak W, Malvindi PG, Bokszanski MP, Perlinski D, Raffa GM et al. Off-pump coronary artery bypass grafting improves short-term outcomes in high-risk patients compared with on-pump coronary artery bypass grafting: meta-analysis. J Thorac Cardiovasc Surg 2016;151:60-77
28. Deppe AC, Arbash W, Kuhn EW, Slottosch I, Scherner M, Liakopoulos OJ et al. Current evidence of coronary artery bypass grafting off-pump versus on-pump: a systematic review with meta-analysis of over 16 900 patients investigated in randomized controlled trials. Eur J Cardiothorac Surg 2016; 49:1031-41
29. Pilarczyk K, Boening A, Jakob H, Langebartels G, Markewitz A, Haake N et al. Preoperative intra-aortic counterpulsation in high-risk patients undergoing cardiac surgery: a meta-analysis of randomized controlled trials. Eur J Cardiothorac Surg 2016;49:5-17
30. Lomivorotov VV, Boboshko VA, Efremov SM, Kornilov IA, Chernyavskiy AMLomivorotov VN et al. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiothorac Vasc Anesth 2012;26: 596-603